GB414495A
(en)
|
1932-06-13 |
1934-08-09 |
Louis Fillipp Gerdetz |
Improvements in flexible cutter chain
|
ZA737247B
(en)
|
1972-09-29 |
1975-04-30 |
Ayerst Mckenna & Harrison |
Rapamycin and process of preparation
|
US4433059A
(en)
|
1981-09-08 |
1984-02-21 |
Ortho Diagnostic Systems Inc. |
Double antibody conjugate
|
US4444878A
(en)
|
1981-12-21 |
1984-04-24 |
Boston Biomedical Research Institute, Inc. |
Bispecific antibody determinants
|
EP0090505B1
(de)
|
1982-03-03 |
1990-08-08 |
Genentech, Inc. |
Menschliches Antithrombin III, DNS Sequenzen dafür, Expressions- und Klonierungsvektoren die solche Sequenzen enthalten und damit transformierte Zellkulturen, Verfahren zur Expression von Menschlichem Antithrombin III und diese enthaltende pharmazeutische Zusammensetzungen
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4882282A
(en)
|
1985-08-16 |
1989-11-21 |
Immunex Corporation |
DNA sequences encoding bovine interleukin-2
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
US5869620A
(en)
|
1986-09-02 |
1999-02-09 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
US5906936A
(en)
|
1988-05-04 |
1999-05-25 |
Yeda Research And Development Co. Ltd. |
Endowing lymphocytes with antibody specificity
|
JPH021556A
(ja)
|
1988-06-09 |
1990-01-05 |
Snow Brand Milk Prod Co Ltd |
ハイブリッド抗体及びその作製方法
|
EP1892296A1
(de)
|
1988-09-02 |
2008-02-27 |
Dyax Corporation |
Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
US6303121B1
(en)
|
1992-07-30 |
2001-10-16 |
Advanced Research And Technology |
Method of using human receptor protein 4-1BB
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
US5399346A
(en)
|
1989-06-14 |
1995-03-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Gene therapy
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
WO1991003493A1
(en)
|
1989-08-29 |
1991-03-21 |
The University Of Southampton |
Bi-or trispecific (fab)3 or (fab)4 conjugates
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
US5273743A
(en)
|
1990-03-09 |
1993-12-28 |
Hybritech Incorporated |
Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
GB9012995D0
(en)
|
1990-06-11 |
1990-08-01 |
Celltech Ltd |
Multivalent antigen-binding proteins
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
EP0585287B1
(de)
|
1990-07-10 |
1999-10-13 |
Cambridge Antibody Technology Limited |
Verfahren zur herstellung von spezifischen bindungspaargliedern
|
DK0564531T3
(da)
|
1990-12-03 |
1998-09-28 |
Genentech Inc |
Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
|
US5582996A
(en)
|
1990-12-04 |
1996-12-10 |
The Wistar Institute Of Anatomy & Biology |
Bifunctional antibodies and method of preparing same
|
AU643109B2
(en)
|
1990-12-14 |
1993-11-04 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
US6319494B1
(en)
|
1990-12-14 |
2001-11-20 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
AU1545692A
(en)
|
1991-03-01 |
1992-10-06 |
Protein Engineering Corporation |
Process for the development of binding mini-proteins
|
IL101147A
(en)
|
1991-03-07 |
2004-06-20 |
Gen Hospital Corp |
Change of direction of cellular immunity by chimera receptors
|
US7049136B2
(en)
|
1991-03-07 |
2006-05-23 |
The General Hospital Corporation |
Redirection of cellular immunity by receptor chimeras
|
US6004811A
(en)
|
1991-03-07 |
1999-12-21 |
The Massachussetts General Hospital |
Redirection of cellular immunity by protein tyrosine kinase chimeras
|
ATE269401T1
(de)
|
1991-04-10 |
2004-07-15 |
Scripps Research Inst |
Bibliotheken heterodimerer rezeptoren mittels phagemiden
|
DE69233482T2
(de)
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
DE4118120A1
(de)
|
1991-06-03 |
1992-12-10 |
Behringwerke Ag |
Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
|
US5199942A
(en)
|
1991-06-07 |
1993-04-06 |
Immunex Corporation |
Method for improving autologous transplantation
|
US6511663B1
(en)
|
1991-06-11 |
2003-01-28 |
Celltech R&D Limited |
Tri- and tetra-valent monospecific antigen-binding proteins
|
LU91067I2
(fr)
|
1991-06-14 |
2004-04-02 |
Genentech Inc |
Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
|
US5637481A
(en)
|
1993-02-01 |
1997-06-10 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
DE4122599C2
(de)
|
1991-07-08 |
1993-11-11 |
Deutsches Krebsforsch |
Phagemid zum Screenen von Antikörpern
|
ES2136092T3
(es)
|
1991-09-23 |
1999-11-16 |
Medical Res Council |
Procedimientos para la produccion de anticuerpos humanizados.
|
US5932448A
(en)
|
1991-11-29 |
1999-08-03 |
Protein Design Labs., Inc. |
Bispecific antibody heterodimers
|
GB9125768D0
(en)
|
1991-12-04 |
1992-02-05 |
Hale Geoffrey |
Therapeutic method
|
CA2507749C
(en)
|
1991-12-13 |
2010-08-24 |
Xoma Corporation |
Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
|
HU215180B
(hu)
|
1992-01-23 |
1998-10-28 |
Merck Patent Gmbh. |
Eljárás monomer és dimer antitest-fragment fúziós fehérjék előállítására
|
AU675929B2
(en)
|
1992-02-06 |
1997-02-27 |
Curis, Inc. |
Biosynthetic binding protein for cancer marker
|
GB9203459D0
(en)
|
1992-02-19 |
1992-04-08 |
Scotgen Ltd |
Antibodies with germ-line variable regions
|
US8211422B2
(en)
|
1992-03-18 |
2012-07-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric receptor genes and cells transformed therewith
|
IL104570A0
(en)
|
1992-03-18 |
1993-05-13 |
Yeda Res & Dev |
Chimeric genes and cells transformed therewith
|
CA2135408A1
(en)
|
1992-05-08 |
1993-11-25 |
Peter C. Keck |
Chimeric multivalent protein analogues and methods of use thereof
|
US6005079A
(en)
|
1992-08-21 |
1999-12-21 |
Vrije Universiteit Brussels |
Immunoglobulins devoid of light chains
|
ES2338321T3
(es)
|
1992-08-21 |
2010-05-06 |
Vrije Universiteit Brussel |
Inmunoglobulinas desprovistas de cadenas ligeras.
|
US5350674A
(en)
|
1992-09-04 |
1994-09-27 |
Becton, Dickinson And Company |
Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
CA2145278C
(en)
|
1992-09-25 |
2009-03-10 |
Peter J. Hudson |
Target binding polypeptide
|
GB9221220D0
(en)
|
1992-10-09 |
1992-11-25 |
Sandoz Ag |
Organic componds
|
GB9221657D0
(en)
|
1992-10-15 |
1992-11-25 |
Scotgen Ltd |
Recombinant bispecific antibodies
|
DE69232604T2
(de)
|
1992-11-04 |
2002-11-07 |
City Of Hope Duarte |
Antikörperkonstrukte
|
GB9323648D0
(en)
|
1992-11-23 |
1994-01-05 |
Zeneca Ltd |
Proteins
|
DK0672142T3
(da)
|
1992-12-04 |
2001-06-18 |
Medical Res Council |
Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
|
US7211259B1
(en)
|
1993-05-07 |
2007-05-01 |
Immunex Corporation |
4-1BB polypeptides and DNA encoding 4-1BB polypeptides
|
US6476198B1
(en)
|
1993-07-13 |
2002-11-05 |
The Scripps Research Institute |
Multispecific and multivalent antigen-binding polypeptide molecules
|
US5635602A
(en)
|
1993-08-13 |
1997-06-03 |
The Regents Of The University Of California |
Design and synthesis of bispecific DNA-antibody conjugates
|
WO1995007984A1
(en)
|
1993-09-16 |
1995-03-23 |
Indiana University Foundation |
Human receptor h4-1bb
|
WO1995009917A1
(en)
|
1993-10-07 |
1995-04-13 |
The Regents Of The University Of California |
Genetically engineered bispecific tetravalent antibodies
|
EP0729471A1
(de)
|
1993-11-19 |
1996-09-04 |
Abbott Laboratories |
Semisynthetische rapamycin analoge mit immunomodulatorischer wirkung
|
SK78196A3
(en)
|
1993-12-17 |
1997-02-05 |
Sandoz Ag |
Rapamycin demethoxy-derivatives, preparation method thereof and pharmaceutical agent containing them
|
US5362718A
(en)
|
1994-04-18 |
1994-11-08 |
American Home Products Corporation |
Rapamycin hydroxyesters
|
ES2185705T3
(es)
|
1994-05-02 |
2003-05-01 |
Bernd Groner |
Proteina bifuncional, preparacion y uso.
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
US5786464C1
(en)
|
1994-09-19 |
2012-04-24 |
Gen Hospital Corp |
Overexpression of mammalian and viral proteins
|
JP3659261B2
(ja)
|
1994-10-20 |
2005-06-15 |
モルフォシス・アクチェンゲゼルシャフト |
組換体タンパク質の多機能性複合体への標的化ヘテロ結合
|
US5712149A
(en)
|
1995-02-03 |
1998-01-27 |
Cell Genesys, Inc. |
Chimeric receptor molecules for delivery of co-stimulatory signals
|
US6103521A
(en)
|
1995-02-06 |
2000-08-15 |
Cell Genesys, Inc. |
Multispecific chimeric receptors
|
EP0871495B1
(de)
|
1995-02-24 |
2005-06-15 |
The General Hospital Corporation |
Neuorientierung der zellulären immunität durch rezeptorchimären
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
DE69633175T2
(de)
|
1995-05-23 |
2005-08-11 |
Morphosys Ag |
Multimere proteine
|
CN1124276C
(zh)
|
1995-06-09 |
2003-10-15 |
诺瓦蒂斯有限公司 |
雷帕霉素衍生物
|
BE1009856A5
(fr)
|
1995-07-14 |
1997-10-07 |
Sandoz Sa |
Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
|
AU6873396A
(en)
|
1995-10-16 |
1997-05-07 |
Unilever N.V. |
A bifunctional or bivalent antibody fragment analogue
|
GB9526131D0
(en)
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Recombinant chimeric receptors
|
WO1997031898A1
(en)
|
1996-02-28 |
1997-09-04 |
Ariad Gene Therapeutics, Inc. |
Synthetic derivatives of rapamycin as multimerizing agents for chimeric proteins with immunophilin-derived domains
|
US5874240A
(en)
|
1996-03-15 |
1999-02-23 |
Human Genome Sciences, Inc. |
Human 4-1BB receptor splicing variant
|
ES2225961T3
(es)
|
1996-04-04 |
2005-03-16 |
Unilever N.V. |
Proteina de union a antigeno multivalente y multiespecifica.
|
US6258823B1
(en)
|
1996-07-12 |
2001-07-10 |
Ariad Pharmaceuticals, Inc. |
Materials and method for treating or preventing pathogenic fungal infection
|
EP1947183B1
(de)
|
1996-08-16 |
2013-07-17 |
Merck Sharp & Dohme Corp. |
Säugerzelloberflächenantigene und damit zusammenhängende Reagenzien
|
US6111090A
(en)
|
1996-08-16 |
2000-08-29 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
US6114148C1
(en)
|
1996-09-20 |
2012-05-01 |
Gen Hospital Corp |
High level expression of proteins
|
CA2269738A1
(en)
|
1996-10-25 |
1998-05-07 |
Mitchell H. Finer |
Targeted cytolysis of cancer cells
|
ATE529509T1
(de)
|
1997-01-21 |
2011-11-15 |
Gen Hospital Corp |
Selektion von proteinen unter verwendung von rna- protein-fusionen
|
AU7266698A
(en)
|
1997-04-30 |
1998-11-24 |
Enzon, Inc. |
Polyalkylene oxide-modified single chain polypeptides
|
US20030207346A1
(en)
|
1997-05-02 |
2003-11-06 |
William R. Arathoon |
Method for making multispecific antibodies having heteromultimeric and common components
|
US20020062010A1
(en)
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
CA2304254C
(en)
|
1997-06-11 |
2012-05-22 |
Hans Christian Thogersen |
Trimerising module
|
EP2380906A2
(de)
|
1997-06-12 |
2011-10-26 |
Novartis International Pharmaceutical Ltd. |
Künstliche Antikörperpolypeptide
|
US20030060444A1
(en)
|
1997-06-25 |
2003-03-27 |
Celltech Therapeutics, Ltd. |
Cell activation process and reagents therefor
|
GB9713473D0
(en)
|
1997-06-25 |
1997-09-03 |
Celltech Therapeutics Ltd |
Biological products
|
US6015815A
(en)
|
1997-09-26 |
2000-01-18 |
Abbott Laboratories |
Tetrazole-containing rapamycin analogs with shortened half-lives
|
TW557297B
(en)
|
1997-09-26 |
2003-10-11 |
Abbott Lab |
Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
|
JP2001520039A
(ja)
|
1997-10-21 |
2001-10-30 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
ヒト腫瘍壊死因子レセプター様タンパク質、tr11,tr11sv1およびtr11sv2
|
DE69841562D1
(de)
|
1997-10-27 |
2010-04-29 |
Bac Ip Bv |
Multivalente antigenbindende proteine
|
ES2210829T3
(es)
|
1997-10-28 |
2004-07-01 |
University Of British Columbia |
Composicion y proceso inmunologico utilizados para modificar transitoriamente la melina del sistema nervioso central de mamiferos para estimular la regeneracion neuronal.
|
ES2234241T3
(es)
|
1998-01-23 |
2005-06-16 |
Vlaams Interuniversitair Instituut Voor Biotechnologie |
Derivados de anticuerpo de multiples fines.
|
WO1999040196A1
(en)
|
1998-02-09 |
1999-08-12 |
Genentech, Inc. |
Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
|
US20040040047A1
(en)
|
1998-03-30 |
2004-02-26 |
Spencer David M. |
Regulated apoptosis using chemically induced dimerization of apoptosis factors
|
HUP9900956A2
(hu)
|
1998-04-09 |
2002-04-29 |
Aventis Pharma Deutschland Gmbh. |
Egyláncú, több antigéntkötőhely kialakítására képes molekulák, előállításuk és alkalmazásuk
|
ATE298248T1
(de)
|
1998-04-15 |
2005-07-15 |
Brigham & Womens Hospital |
T-zell inhibierende rezeptorzusammensetzungen sowie deren verwendung
|
DE19819846B4
(de)
|
1998-05-05 |
2016-11-24 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Multivalente Antikörper-Konstrukte
|
GB9809658D0
(en)
|
1998-05-06 |
1998-07-01 |
Celltech Therapeutics Ltd |
Biological products
|
GB9812545D0
(en)
|
1998-06-10 |
1998-08-05 |
Celltech Therapeutics Ltd |
Biological products
|
JP2002521053A
(ja)
|
1998-07-28 |
2002-07-16 |
マイクロメット アーゲー |
ヘテロミニ体
|
WO2000014257A1
(en)
|
1998-09-04 |
2000-03-16 |
Sloan-Kettering Institute For Cancer Research |
Fusion receptors specific for prostate-specific membrane antigen and uses thereof
|
AU2472400A
(en)
*
|
1998-10-20 |
2000-05-08 |
City Of Hope |
CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
|
US6333396B1
(en)
|
1998-10-20 |
2001-12-25 |
Enzon, Inc. |
Method for targeted delivery of nucleic acids
|
US7052906B1
(en)
|
1999-04-16 |
2006-05-30 |
Celltech R & D Limited |
Synthetic transmembrane components
|
US7527787B2
(en)
|
2005-10-19 |
2009-05-05 |
Ibc Pharmaceuticals, Inc. |
Multivalent immunoglobulin-based bioactive assemblies
|
US7534866B2
(en)
|
2005-10-19 |
2009-05-19 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
ES2295040T3
(es)
|
1999-07-12 |
2008-04-16 |
Genentech, Inc. |
Promocion o inhibicion de la angiogenesis y cardiovascularizacion mediante homologos del ligando / receptor del factor de necrosis del tumor.
|
AU1086501A
(en)
|
1999-10-15 |
2001-04-30 |
Carnegie Institution Of Washington |
Rna interference pathway genes as tools for targeted genetic interference
|
GB9925848D0
(en)
|
1999-11-01 |
1999-12-29 |
Celltech Therapeutics Ltd |
Biological products
|
US6326193B1
(en)
|
1999-11-05 |
2001-12-04 |
Cambria Biosciences, Llc |
Insect control agent
|
CA2391129A1
(en)
|
1999-11-10 |
2001-05-17 |
The Uab Research Foundation |
Lentiviral vector transduction of hematopoietic stem cells
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
AU2001243288B2
(en)
|
2000-02-24 |
2005-11-24 |
Life Technologies Corporation |
Simultaneous stimulation and concentration of cells
|
CN101289511A
(zh)
|
2000-04-11 |
2008-10-22 |
杰南技术公司 |
多价抗体及其应用
|
WO2001090192A2
(en)
|
2000-05-24 |
2001-11-29 |
Imclone Systems Incorporated |
Bispecific immunoglobulin-like antigen binding proteins and method of production
|
IL136511A0
(en)
|
2000-06-01 |
2001-06-14 |
Gavish Galilee Bio Appl Ltd |
Genetically engineered mhc molecules
|
AU2001275474A1
(en)
|
2000-06-12 |
2001-12-24 |
Akkadix Corporation |
Materials and methods for the control of nematodes
|
CA2410551A1
(en)
|
2000-06-30 |
2002-01-10 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) |
Heterodimeric fusion proteins
|
AU2001283496A1
(en)
|
2000-07-25 |
2002-02-05 |
Immunomedics, Inc. |
Multivalent target binding protein
|
GB0025307D0
(en)
|
2000-10-16 |
2000-11-29 |
Celltech Chiroscience Ltd |
Biological products
|
KR100870123B1
(ko)
|
2000-10-20 |
2008-11-25 |
츄가이 세이야꾸 가부시키가이샤 |
저분자화 아고니스트 항체
|
ATE338124T1
(de)
|
2000-11-07 |
2006-09-15 |
Hope City |
Cd19-spezifische umgezielte immunzellen
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
AU2002247826A1
(en)
|
2001-03-13 |
2002-09-24 |
University College London |
Specific binding members
|
CN1294148C
(zh)
|
2001-04-11 |
2007-01-10 |
中国科学院遗传与发育生物学研究所 |
环状单链三特异抗体
|
US7070995B2
(en)
|
2001-04-11 |
2006-07-04 |
City Of Hope |
CE7-specific redirected immune cells
|
US7514537B2
(en)
|
2001-04-30 |
2009-04-07 |
City Of Hope |
Chimeric immunoreceptor useful in treating human gliomas
|
JP4448282B2
(ja)
|
2001-04-30 |
2010-04-07 |
シティ・オブ・ホープ |
ヒト癌を処置するのに有用なキメライムノレセプター
|
US20090257994A1
(en)
|
2001-04-30 |
2009-10-15 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
DK1399484T3
(da)
|
2001-06-28 |
2010-11-08 |
Domantis Ltd |
Dobbelt-specifik ligand og anvendelse af denne
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
US20050043519A1
(en)
|
2001-08-10 |
2005-02-24 |
Helen Dooley |
Antigen binding domains
|
ES2276735T3
(es)
|
2001-09-14 |
2007-07-01 |
Affimed Therapeutics Ag |
Anticuerpos fv multimericos de cadena sencilla en tandem.
|
ATE434040T1
(de)
|
2001-10-01 |
2009-07-15 |
Dyax Corp |
Mehrkettige eukaryontische display-vektoren und deren verwendungen
|
US20030148982A1
(en)
|
2001-11-13 |
2003-08-07 |
Brenner Malcolm K. |
Bi-spcific chimeric T cells
|
US20030211078A1
(en)
|
2001-12-07 |
2003-11-13 |
Heavner George A. |
Pseudo-antibody constructs
|
US7638326B2
(en)
|
2002-01-03 |
2009-12-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform
|
AU2003202908A1
(en)
|
2002-01-03 |
2003-07-24 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of t-cells using an engineered multivalent signaling platform
|
US7745140B2
(en)
|
2002-01-03 |
2010-06-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
|
PT1478648E
(pt)
|
2002-02-01 |
2014-07-15 |
Ariad Pharma Inc |
Compostos contendo fósforo e suas utilizações
|
US20040018557A1
(en)
|
2002-03-01 |
2004-01-29 |
Immunomedics, Inc. |
Bispecific antibody point mutations for enhancing rate of clearance
|
GB0208104D0
(en)
|
2002-04-09 |
2002-05-22 |
Univ Dundee |
Method
|
ATE512989T1
(de)
|
2002-04-15 |
2011-07-15 |
Chugai Pharmaceutical Co Ltd |
Verfahren zur herstellung von scdb-bibliotheken
|
TWI275390B
(en)
|
2002-04-30 |
2007-03-11 |
Wyeth Corp |
Process for the preparation of 7-substituted-3- quinolinecarbonitriles
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
CN1678634A
(zh)
|
2002-06-28 |
2005-10-05 |
多曼蒂斯有限公司 |
免疫球蛋白单个变体抗原结合区及其特异性构建体
|
US20040047858A1
(en)
|
2002-09-11 |
2004-03-11 |
Blumberg Richard S. |
Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
|
US7488802B2
(en)
|
2002-12-23 |
2009-02-10 |
Wyeth |
Antibodies against PD-1
|
GB0230203D0
(en)
|
2002-12-27 |
2003-02-05 |
Domantis Ltd |
Fc fusion
|
US20050129671A1
(en)
|
2003-03-11 |
2005-06-16 |
City Of Hope |
Mammalian antigen-presenting T cells and bi-specific T cells
|
GB0305702D0
(en)
|
2003-03-12 |
2003-04-16 |
Univ Birmingham |
Bispecific antibodies
|
AU2004232928A1
(en)
|
2003-04-22 |
2004-11-04 |
Ibc Pharmaceuticals |
Polyvalent protein complex
|
US7402431B2
(en)
|
2004-03-01 |
2008-07-22 |
Immunovative Therapies, Ltd. |
T-cell therapy formulation
|
BRPI0410785A
(pt)
|
2003-05-23 |
2006-06-20 |
Wyeth Corp |
molécula de ácido nucleico isolada, célula hospedeira, animal transgênico não humano, proteìna isolada, oligonucleotìdeo anti-sentido, molécula de sirna, anticorpo isolado, métodos de triagem quanto aos compostos de teste capazes de inibir, de intensificar ou imitar a interação do gitrl com o gitr, para diagnosticar doenças, para tratar um paciente em risco ou diagnosticado com uma doença, para induzir e para inibir a proliferação de uma população celular contendo células t efetoras, de bloquear a supressão e de supressão de uma população celular que inclua células t efetoras na presença de células t reguladoras cd4+cd25+, e para tratar uma doença, composição farmacêutica, e, adjuvante de vacina
|
CA2529945A1
(en)
|
2003-06-27 |
2005-01-06 |
Biogen Idec Ma Inc. |
Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
|
KR20060041205A
(ko)
|
2003-07-01 |
2006-05-11 |
이뮤노메딕스, 인코오포레이티드 |
양특이성 항체들의 다가 담체들
|
WO2005007190A1
(en)
|
2003-07-11 |
2005-01-27 |
Schering Corporation |
Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
|
US7696322B2
(en)
|
2003-07-28 |
2010-04-13 |
Catalent Pharma Solutions, Inc. |
Fusion antibodies
|
EP1660186B1
(de)
|
2003-08-18 |
2013-12-25 |
MedImmune, LLC |
Humanisierung von antikörpern
|
CA2537055A1
(en)
|
2003-08-22 |
2005-04-21 |
Medimmune, Inc. |
Humanization of antibodies
|
WO2005019429A2
(en)
|
2003-08-22 |
2005-03-03 |
Potentia Pharmaceuticals, Inc. |
Compositions and methods for enhancing phagocytosis or phagocyte activity
|
WO2005035586A1
(ja)
|
2003-10-08 |
2005-04-21 |
Kyowa Hakko Kogyo Co., Ltd. |
融合蛋白質組成物
|
US20050113564A1
(en)
|
2003-11-05 |
2005-05-26 |
St. Jude Children's Research Hospital |
Chimeric receptors with 4-1BB stimulatory signaling domain
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
US7220755B2
(en)
|
2003-11-12 |
2007-05-22 |
Biosensors International Group, Ltd. |
42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
|
EP2204385A1
(de)
*
|
2003-11-25 |
2010-07-07 |
The Government Of U.S.A, As Represented By Secretary, Department of Health and Human Sevices |
Mutanten des Exotoxin A von Pseudomonas und deren Verwendungen
|
EP1692318A4
(de)
|
2003-12-02 |
2008-04-02 |
Genzyme Corp |
Zusammensetzungen und verfahren zur diagnose und behandlung von lungenkrebs
|
CA2550996A1
(en)
|
2003-12-22 |
2005-07-14 |
Centocor, Inc. |
Methods for generating multimeric molecules
|
GB0329825D0
(en)
|
2003-12-23 |
2004-01-28 |
Celltech R&D Ltd |
Biological products
|
US20050266425A1
(en)
|
2003-12-31 |
2005-12-01 |
Vaccinex, Inc. |
Methods for producing and identifying multispecific antibodies
|
US8383575B2
(en)
|
2004-01-30 |
2013-02-26 |
Paul Scherrer Institut |
(DI)barnase-barstar complexes
|
GB0409799D0
(en)
|
2004-04-30 |
2004-06-09 |
Isis Innovation |
Method of generating improved immune response
|
EP3363907A1
(de)
|
2004-05-27 |
2018-08-22 |
The Trustees of the University of Pennsylvania |
Neue künstliches antigen präsentierende zellen und verwendungen dafür
|
WO2006083289A2
(en)
|
2004-06-04 |
2006-08-10 |
Duke University |
Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
|
EP1786918A4
(de)
|
2004-07-17 |
2009-02-11 |
Imclone Systems Inc |
Neuer tetravalenter bispezifischer antikörper
|
JP2008511337A
(ja)
|
2004-09-02 |
2008-04-17 |
ジェネンテック・インコーポレーテッド |
ヘテロ多量体分子
|
WO2006036445A2
(en)
|
2004-09-24 |
2006-04-06 |
Trustees Of Dartmouth College |
Chimeric nk receptor and methods for treating cancer
|
EP1827604B1
(de)
|
2004-12-10 |
2019-11-20 |
Peter MacCallum Cancer Institute |
Verfahren und zusammensetzungen für die adoptive immuntherapie
|
PT2343320T
(pt)
|
2005-03-25 |
2018-01-23 |
Gitr Inc |
Anticorpos anti-gitr e as suas utilizações
|
AU2006232287B2
(en)
|
2005-03-31 |
2011-10-06 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for producing polypeptides by regulating polypeptide association
|
AU2006232920B2
(en)
|
2005-04-06 |
2011-09-29 |
Ibc Pharmaceuticals, Inc. |
Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
|
EP1868650B1
(de)
|
2005-04-15 |
2018-10-03 |
MacroGenics, Inc. |
Kovalente diabodies und ihre verwendung
|
CA3151350A1
(en)
|
2005-05-09 |
2006-11-16 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
US8124084B2
(en)
|
2005-05-17 |
2012-02-28 |
University Of Connecticut |
Compositions and methods for immunomodulation in an organism using IL-15 and soluble IL-15Ra
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
US20060263367A1
(en)
|
2005-05-23 |
2006-11-23 |
Fey Georg H |
Bispecific antibody devoid of Fc region and method of treatment using same
|
EA019344B1
(ru)
|
2005-07-01 |
2014-03-31 |
МЕДАРЕКС, Эл.Эл.Си. |
Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
|
US20070036773A1
(en)
|
2005-08-09 |
2007-02-15 |
City Of Hope |
Generation and application of universal T cells for B-ALL
|
EP2495257A3
(de)
|
2005-08-19 |
2012-10-17 |
Abbott Laboratories |
Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
ATE452913T1
(de)
|
2005-08-26 |
2010-01-15 |
Pls Design Gmbh |
Bivalente igy antikörperkonstrukte für diagnostische und therapeutische anwendungen
|
CN103819416A
(zh)
|
2005-10-07 |
2014-05-28 |
埃克塞里艾克西斯公司 |
N-(3-氨基-喹喔啉-2-基)-磺酰胺衍生物及其作为磷脂酰肌醇3-激酶抑制剂的用途
|
WO2007044887A2
(en)
|
2005-10-11 |
2007-04-19 |
Transtarget, Inc. |
Method for producing a population of homogenous tetravalent bispecific antibodies
|
US8623356B2
(en)
|
2005-11-29 |
2014-01-07 |
The University Of Sydney |
Demibodies: dimerization-activated therapeutic agents
|
PT2529747T
(pt)
|
2005-12-02 |
2018-05-09 |
Icahn School Med Mount Sinai |
Vírus da doença de newcastle quiméricos que apresentam proteínas de superfície não nativas e suas utilizações
|
CN102796743B
(zh)
|
2006-01-13 |
2015-11-18 |
美国政府健康及人类服务部国立卫生研究院 |
用于在哺乳动物细胞中表达的密码子优化的IL-15和IL-15Rα基因
|
WO2007133822A1
(en)
|
2006-01-19 |
2007-11-22 |
Genzyme Corporation |
Gitr antibodies for the treatment of cancer
|
CA2638794A1
(en)
|
2006-02-15 |
2007-08-23 |
Imclone Systems Incorporated |
Functional antibodies
|
SG170750A1
(en)
|
2006-03-17 |
2011-05-30 |
Biogen Idec Inc |
Stabilized polypeptide compositions
|
AU2007229698B9
(en)
|
2006-03-24 |
2012-11-08 |
Merck Patent Gmbh |
Engineered heterodimeric protein domains
|
US8946391B2
(en)
|
2006-03-24 |
2015-02-03 |
The Regents Of The University Of California |
Construction of a multivalent scFv through alkyne-azide 1,3-dipolar cycloaddition
|
EP2009101B1
(de)
|
2006-03-31 |
2017-10-25 |
Chugai Seiyaku Kabushiki Kaisha |
Antikörpermodifikationsverfahren für die aufreinigung eines bispezifischen antikörpers
|
EP2027153B1
(de)
|
2006-05-25 |
2014-04-30 |
Bayer Intellectual Property GmbH |
Dimäre molekularkomplexe
|
US20070274985A1
(en)
|
2006-05-26 |
2007-11-29 |
Stefan Dubel |
Antibody
|
EP2418223A3
(de)
|
2006-06-12 |
2013-01-16 |
Emergent Product Development Seattle, LLC |
Einkettige, multivalente Bindungsproteine mit Effektorfunktion
|
US7741446B2
(en)
|
2006-08-18 |
2010-06-22 |
Armagen Technologies, Inc. |
Fusion antibodies that cross the blood-brain barrier in both directions
|
US10118970B2
(en)
|
2006-08-30 |
2018-11-06 |
Genentech, Inc. |
Multispecific antibodies
|
US20100105136A1
(en)
|
2006-10-09 |
2010-04-29 |
The General Hospital Corporation |
Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
|
EP1916259A1
(de)
|
2006-10-26 |
2008-04-30 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Anti-Glycoprotein VI SCFV Fragment zur Thrombosebehandlung
|
CN101965363A
(zh)
|
2006-11-02 |
2011-02-02 |
丹尼尔·J·卡鹏 |
具有活动部分的杂合免疫球蛋白
|
US20080131415A1
(en)
|
2006-11-30 |
2008-06-05 |
Riddell Stanley R |
Adoptive transfer of cd8 + t cell clones derived from central memory cells
|
WO2008140621A2
(en)
|
2006-12-21 |
2008-11-20 |
Mount Sinai School Of Medicine Of New York University |
Transgenic oncolytic viruses and uses thereof
|
CA2584494A1
(en)
|
2007-03-27 |
2008-09-27 |
Jeffrey A. Medin |
Vector encoding therapeutic polypeptide and safety elements to clear transduced cells
|
EP2626372B1
(de)
|
2007-03-29 |
2018-03-21 |
Genmab A/S |
Bispezifische Antikörper und Verfahren zu deren Herstellung
|
EP2141997B1
(de)
|
2007-03-30 |
2012-10-31 |
Memorial Sloan-Kettering Cancer Center |
Konstitutive expression kostimulierender liganden auf adoptiv transferierten t-lymphozyten
|
US20080260738A1
(en)
|
2007-04-18 |
2008-10-23 |
Moore Margaret D |
Single chain fc, methods of making and methods of treatment
|
AU2008266952A1
(en)
|
2007-06-12 |
2008-12-24 |
Trubion Pharmaceuticals, Inc. |
Anti-CD20 therapeutic compositions and methods
|
PT2170959E
(pt)
|
2007-06-18 |
2014-01-07 |
Merck Sharp & Dohme |
Anticorpos para o receptor humano de morte programada pd-1
|
NZ616254A
(en)
|
2007-06-27 |
2015-04-24 |
Us Sec Dep Of Health And Human Services |
Complexes of il-15 and il-15ralpha and uses thereof
|
DK2175884T3
(en)
|
2007-07-12 |
2016-09-26 |
Gitr Inc |
Combination USING GITR BINDING MOLECULES
|
KR20100058509A
(ko)
|
2007-07-31 |
2010-06-03 |
메디뮨 엘엘씨 |
다중특이적 에피토프 결합 단백질 및 이의 용도
|
WO2009021754A2
(en)
|
2007-08-15 |
2009-02-19 |
Bayer Schering Pharma Aktiengesellschaft |
Monospecific and multispecific antibodies and method of use
|
WO2009052623A1
(en)
|
2007-10-26 |
2009-04-30 |
Governing Council Of The University Of Toronto |
Therapeutic and diagnostic methods using tim-3
|
EP2215125A1
(de)
|
2007-11-27 |
2010-08-11 |
Ablynx N.V. |
Verfahren zur gewinnung von polypeptidkonstrukten mit zwei oder mehreren einzeldomänenantikörpern
|
ES2614284T3
(es)
|
2007-11-30 |
2017-05-30 |
Glaxo Group Limited |
Construcciones de unión a antígenos
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
US8227577B2
(en)
|
2007-12-21 |
2012-07-24 |
Hoffman-La Roche Inc. |
Bivalent, bispecific antibodies
|
US8242247B2
(en)
|
2007-12-21 |
2012-08-14 |
Hoffmann-La Roche Inc. |
Bivalent, bispecific antibodies
|
WO2009089004A1
(en)
|
2008-01-07 |
2009-07-16 |
Amgen Inc. |
Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
|
WO2009091826A2
(en)
|
2008-01-14 |
2009-07-23 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
|
US10059923B2
(en)
|
2008-01-30 |
2018-08-28 |
Memorial Sloan Kettering Cancer Center |
Methods for off-the-shelf tumor immunotherapy using allogeneic T-cell precursors
|
JP2011512332A
(ja)
|
2008-02-11 |
2011-04-21 |
キュアー テック リミテッド |
腫瘍治療のためのモノクローナル抗体
|
JP2011512395A
(ja)
|
2008-02-21 |
2011-04-21 |
アストラゼネカ アクチボラグ |
組合せ療法238
|
US8379824B2
(en)
|
2008-03-06 |
2013-02-19 |
At&T Intellectual Property I, Lp |
Methods and apparatus to provide a network-based caller identification service in a voice over internet protocol network
|
EP2262837A4
(de)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
Pd-1-bindende proteine
|
KR101280716B1
(ko)
|
2008-03-25 |
2013-07-01 |
로슈 글리카트 아게 |
비-호지킨 림프종의 치료를 위한, 시클로포스파미드, 빈크리스틴 및 독소루비신과 조합으로의 증가된 항체 의존성 세포 세포독성 (adcc) 을 갖는 유형 ⅱ 항-cd20 항체의 용도
|
CA2729810A1
(en)
|
2008-07-02 |
2010-01-07 |
Emergent Product Development Seattle, Llc |
Tgf-.beta. antagonist multi-target binding proteins
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
CN102203125A
(zh)
|
2008-08-25 |
2011-09-28 |
安普利穆尼股份有限公司 |
Pd-1拮抗剂及其使用方法
|
CN102203132A
(zh)
|
2008-08-25 |
2011-09-28 |
安普利穆尼股份有限公司 |
Pd-1拮抗剂的组合物和使用方法
|
JP2012501180A
(ja)
|
2008-08-26 |
2012-01-19 |
シティ・オブ・ホープ |
T細胞の抗腫瘍エフェクター機能増進のための方法および組成物
|
WO2010030002A1
(ja)
|
2008-09-12 |
2010-03-18 |
国立大学法人三重大学 |
外来性gitrリガンド発現細胞
|
US8476431B2
(en)
|
2008-11-03 |
2013-07-02 |
Itellikine LLC |
Benzoxazole kinase inhibitors and methods of use
|
MX356367B
(es)
|
2008-12-09 |
2018-05-25 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
|
EP2389443B1
(de)
|
2009-01-23 |
2018-11-14 |
Roger Williams Hospital |
Retrovirale vektoren kodierend für multiple stark homologe nichtvirale polypeptide und ihre verwendung
|
JP2012516153A
(ja)
|
2009-01-29 |
2012-07-19 |
アボット・ラボラトリーズ |
Il−1結合タンパク質
|
EP2393921B1
(de)
|
2009-02-05 |
2015-07-15 |
Icahn School of Medicine at Mount Sinai |
Chimäres newcastle disease virus und seine verwendungen
|
EP3192811A1
(de)
|
2009-02-09 |
2017-07-19 |
Université d'Aix-Marseille |
Pd1-antikörper und pd-l1-antikörper sowie zugehörige verwendungen
|
CA2753158A1
(en)
|
2009-02-23 |
2010-08-26 |
Glenmark Pharmaceuticals S.A. |
Humanized antibodies that bind to cd19 and their uses
|
RU2506264C2
(ru)
|
2009-04-03 |
2014-02-10 |
Вэрастэм, Инк. |
Пиримидин-замещенные пуриновые соединения в качестве ингибиторов киназы (или киназ)
|
AU2010245011B2
(en)
|
2009-04-27 |
2015-09-03 |
Oncomed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
ES2668874T3
(es)
|
2009-04-30 |
2018-05-22 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Anticuerpos anti-CEACAM1 y métodos de uso de los mismos
|
AU2010282280B2
(en)
|
2009-08-14 |
2016-06-09 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Use of IL-15 to increase thymic output and to treat lymphopenia
|
US8709424B2
(en)
|
2009-09-03 |
2014-04-29 |
Merck Sharp & Dohme Corp. |
Anti-GITR antibodies
|
US8465743B2
(en)
|
2009-10-01 |
2013-06-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
|
US9181527B2
(en)
|
2009-10-29 |
2015-11-10 |
The Trustees Of Dartmouth College |
T cell receptor-deficient T cell compositions
|
GB0919054D0
(en)
|
2009-10-30 |
2009-12-16 |
Isis Innovation |
Treatment of obesity
|
WO2011066342A2
(en)
|
2009-11-24 |
2011-06-03 |
Amplimmune, Inc. |
Simultaneous inhibition of pd-l1/pd-l2
|
NZ600820A
(en)
|
2009-12-29 |
2014-12-24 |
Emergent Product Dev Seattle |
Heterodimer binding proteins and uses thereof
|
CA2791975C
(en)
|
2010-02-04 |
2021-02-09 |
The Trustees Of The University Of Pennsylvania |
Icos critically regulates the expansion and function of inflammatory human th17 cells
|
AU2011244282A1
(en)
|
2010-04-20 |
2012-11-15 |
Genmab A/S |
Heterodimeric antibody Fc-containing proteins and methods for production thereof
|
US9089520B2
(en)
|
2010-05-21 |
2015-07-28 |
Baylor College Of Medicine |
Methods for inducing selective apoptosis
|
WO2011159847A2
(en)
|
2010-06-15 |
2011-12-22 |
The Regents Of The University Of California |
Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof
|
WO2011159877A2
(en)
|
2010-06-18 |
2011-12-22 |
The Brigham And Women's Hospital, Inc. |
Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
|
KR20130098301A
(ko)
|
2010-07-09 |
2013-09-04 |
엑셀리시스, 인코포레이티드 |
암 치료를 위한 키나제 억제제들의 병용물
|
BR112013001088A2
(pt)
|
2010-07-16 |
2016-05-24 |
Piramal Entpr Ltd |
"derivados substituídos como inibidores a quinase de imidazoquinolina"
|
CA2816379A1
(en)
|
2010-10-27 |
2012-05-03 |
Baylor College Of Medicine |
Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
|
TR201820015T4
(tr)
|
2010-12-09 |
2019-01-21 |
Univ Pennsylvania |
Kanser Tedavisi İçin Kimerik Antijen Reseptörü-Modifiye Edilmiş T Hücrelerinin Kullanılması
|
JP5897035B2
(ja)
|
2010-12-14 |
2016-03-30 |
ユニバーシティ オブ メリーランド,ボルチモア |
汎用の抗タグキメラ抗原受容体発現t細胞及びがんを治療する方法
|
EA201391059A1
(ru)
|
2011-01-18 |
2014-05-30 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
Композиции для лечения рака и способы их применения
|
WO2012127464A2
(en)
|
2011-03-23 |
2012-09-27 |
Gavish-Galilee Bio Applications Ltd |
Constitutively activated t cells for use in adoptive cell therapy
|
NZ743310A
(en)
|
2011-03-23 |
2022-11-25 |
Fred Hutchinson Cancer Center |
Method and compositions for cellular immunotherapy
|
WO2012135854A2
(en)
|
2011-04-01 |
2012-10-04 |
Memorial Sloan-Kettering Cancer Center |
Antibodies to cytosolic peptides
|
AU2012240562B2
(en)
|
2011-04-08 |
2016-12-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer
|
ES2649967T3
(es)
|
2011-04-08 |
2018-01-16 |
Baylor College Of Medicine |
Inversión de los efectos del microentorno tumoral utilizando receptores quiméricos de citocinas
|
US20130071414A1
(en)
|
2011-04-27 |
2013-03-21 |
Gianpietro Dotti |
Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
|
US8841418B2
(en)
|
2011-07-01 |
2014-09-23 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to TIM3
|
ES2648169T3
(es)
|
2011-07-25 |
2017-12-28 |
Nationwide Children's Hospital, Inc. |
Productos de virus recombinantes y métodos para inhibición de la expresión de DUX4
|
CN104114233B
(zh)
|
2011-07-29 |
2021-11-12 |
宾夕法尼亚大学董事会 |
转换共刺激受体
|
EP2741749A4
(de)
|
2011-08-11 |
2015-04-15 |
Intellikine Llc |
Kinasehemmende polymorphe
|
WO2013033626A2
(en)
|
2011-08-31 |
2013-03-07 |
Trustees Of Dartmouth College |
Nkp30 receptor targeted therapeutics
|
WO2013039954A1
(en)
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anti-gitr antibodies
|
US10421960B2
(en)
|
2011-09-16 |
2019-09-24 |
The Trustees Of The University Of Pennsylvania |
RNA engineered T cells for the treatment of cancer
|
DK2755487T3
(en)
|
2011-09-16 |
2019-04-08 |
Baylor College Medicine |
TARGETATION OF THE TUMORMICROMY ENVIRONMENT USING MANIPULATED NKT CELLS
|
WO2013054320A1
(en)
|
2011-10-11 |
2013-04-18 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
|
CA2851795C
(en)
|
2011-10-20 |
2018-11-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-cd22 chimeric antigen receptors
|
DK2771364T3
(da)
|
2011-10-27 |
2019-08-19 |
Genmab As |
Fremstilling af heterodimere proteiner
|
WO2013082366A1
(en)
|
2011-12-01 |
2013-06-06 |
The Brigham And Women's Hospital, Inc. |
Anti-ceacam1 recombinant antibodies for cancer therapy
|
CA2861491C
(en)
*
|
2012-02-13 |
2020-08-25 |
Seattle Children's Hospital D/B/A Seattle Children's Research Institute |
Bispecific chimeric antigen receptors and therapeutic uses thereof
|
ES2959443T3
(es)
|
2012-02-22 |
2024-02-26 |
Univ Pennsylvania |
Uso del dominio de señalización de CD2 en receptores de antígenos quiméricos de segunda generación
|
EP3747898B1
(de)
|
2012-02-22 |
2023-03-15 |
The Trustees of the University of Pennsylvania |
Verwendung von cars auf icos-basis zur verbesserung einer antitumor-wirkung und einer car-persistenz
|
BR112014020499A2
(pt)
|
2012-02-22 |
2019-09-24 |
Univ Pennsylvania |
sequência de ácido nucleico isolada, célula - t, vetor, e, população persistente de células - t
|
GB2537000C
(en)
|
2012-05-25 |
2019-10-09 |
Univ California |
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
|
CN112375846A
(zh)
|
2012-07-13 |
2021-02-19 |
宾夕法尼亚大学董事会 |
评估用于施用的转导t细胞的适用性的方法
|
ES2786263T3
(es)
|
2012-07-13 |
2020-10-09 |
Univ Pennsylvania |
Mejora de la actividad de los CAR de linfocitos T mediante la introducción conjunta de un anticuerpo biespecífico
|
LT2872171T
(lt)
|
2012-07-13 |
2021-04-26 |
The Trustees Of The University Of Pennsylvania |
Car priešnavikinio aktyvumo toksiškumo reguliavimas
|
KR102216083B1
(ko)
|
2012-07-13 |
2021-02-17 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
정상 b 세포를 고갈시켜 내성을 유도하기 위한 cart19의 용도
|
WO2014011993A2
(en)
|
2012-07-13 |
2014-01-16 |
The Trustees Of The University Of Pennsylvania |
Epitope spreading associated with car t-cells
|
JP2015525765A
(ja)
|
2012-07-13 |
2015-09-07 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
Cart細胞を調節するための組成物および方法
|
EP2879709B1
(de)
|
2012-07-31 |
2020-01-08 |
The Brigham and Women's Hospital, Inc. |
Modulation der immunreaktion
|
IL293944A
(en)
|
2012-08-20 |
2022-08-01 |
Hutchinson Fred Cancer Res |
Method and preparations for cellular immunotherapy
|
WO2014039513A2
(en)
|
2012-09-04 |
2014-03-13 |
The Trustees Of The University Of Pennsylvania |
Inhibition of diacylglycerol kinase to augment adoptive t cell transfer
|
EP2904106A4
(de)
|
2012-10-01 |
2016-05-11 |
Univ Pennsylvania |
Zusammensetzungen und verfahren zum anzielung von stromazellen zur behandlung von krebs
|
US10117896B2
(en)
|
2012-10-05 |
2018-11-06 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
CN104853776B
(zh)
|
2012-10-12 |
2021-04-09 |
布里格姆及妇女医院股份有限公司 |
免疫应答的增强
|
US20160008399A1
(en)
|
2013-01-14 |
2016-01-14 |
Fred Hutchinson Cancer Research Center |
Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse
|
MX369545B
(es)
|
2013-02-15 |
2019-11-12 |
Univ California |
Receptor de antígeno químerico y métodos para usarlo.
|
ES2814962T3
(es)
|
2013-02-20 |
2021-03-29 |
Novartis Ag |
Fijación eficaz como objetivo de la leucemia humana primaria utilizando células T modificadas con receptor de antígeno quimérico anti-CD123
|
US9394368B2
(en)
|
2013-02-20 |
2016-07-19 |
Novartis Ag |
Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor
|
ES2671004T3
(es)
|
2013-03-07 |
2018-06-04 |
Baylor College Of Medicine |
Dirección a CD138 en cáncer
|
US9434935B2
(en)
|
2013-03-10 |
2016-09-06 |
Bellicum Pharmaceuticals, Inc. |
Modified caspase polypeptides and uses thereof
|
WO2014151960A2
(en)
|
2013-03-14 |
2014-09-25 |
Bellicum Pharmaceuticals, Inc. |
Methods for controlling t cell proliferation
|
NZ711946A
(en)
|
2013-03-14 |
2020-05-29 |
Icahn School Med Mount Sinai |
Newcastle disease viruses and uses thereof
|
EP3623380A1
(de)
|
2013-03-15 |
2020-03-18 |
Michael C. Milone |
Targeting von zytotoxischen zellen mit chimären rezeptoren zur adoptiven immuntherapie
|
TWI654206B
(zh)
|
2013-03-16 |
2019-03-21 |
諾華公司 |
使用人類化抗-cd19嵌合抗原受體治療癌症
|
EP3004329B1
(de)
|
2013-06-05 |
2020-03-04 |
Bellicum Pharmaceuticals, Inc. |
Verfahren zur induktion von partieller apoptose mit caspasepolypeptiden
|
AU2014348657A1
(en)
|
2013-11-13 |
2016-05-19 |
Novartis Ag |
mTOR inhibitors for enhancing the immune response
|
DK3071223T3
(da)
|
2013-11-21 |
2021-03-29 |
Autolus Ltd |
Cell
|
US9512084B2
(en)
|
2013-11-29 |
2016-12-06 |
Novartis Ag |
Amino pyrimidine derivatives
|
RU2714902C2
(ru)
|
2013-12-19 |
2020-02-20 |
Новартис Аг |
Химерные рецепторы антигена против мезотелина человека и их применение
|
EP3087101B1
(de)
|
2013-12-20 |
2024-06-05 |
Novartis AG |
Regulierbarer chimärer antigenrezeptor
|
US11028143B2
(en)
|
2014-01-21 |
2021-06-08 |
Novartis Ag |
Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules
|
EP3119425B1
(de)
|
2014-03-15 |
2020-09-23 |
Novartis AG |
Regulierbarer chimärer antigenrezeptor
|
JP2017513818A
(ja)
|
2014-03-15 |
2017-06-01 |
ノバルティス アーゲー |
キメラ抗原受容体を使用する癌の処置
|
MX2016013239A
(es)
|
2014-04-07 |
2017-05-03 |
Novartis Ag |
Tratamiento de cancer utilizando receptor quimerico de antigeno anti-cd19.
|
CA2955465A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Treatment of cancer using a cll-1 chimeric antigen receptor
|
US20170274014A1
(en)
|
2014-07-21 |
2017-09-28 |
Jennifer Brogdon |
Combinations of low, immune enhancing, doses of mtor inhibitors and cars
|
ES2805475T3
(es)
|
2014-07-21 |
2021-02-12 |
Novartis Ag |
Tratamiento del cáncer utilizando un receptor antigénico quimérico de CD33
|
WO2016014501A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase molecules and uses thereof
|
SG11201700476VA
(en)
|
2014-07-21 |
2017-02-27 |
Novartis Ag |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のmTOR阻害剤とCARの組み合わせ
|
WO2016019300A1
(en)
|
2014-07-31 |
2016-02-04 |
Novartis Ag |
Subset-optimized chimeric antigen receptor-containing t-cells
|
EP3180359A1
(de)
|
2014-08-14 |
2017-06-21 |
Novartis AG |
Behandlung von krebs mit einem chimären gfr-alpha-4-antigenrezeptor
|
PL3183268T3
(pl)
|
2014-08-19 |
2020-09-07 |
Novartis Ag |
Chimeryczny receptor antygenowy (CAR) anty-CD123 do zastosowania w leczeniu nowotworu złośliwego
|
ES2891332T3
(es)
|
2014-09-17 |
2022-01-27 |
Novartis Ag |
Direccionamiento a células citotóxicas con receptores quiméricos para la inmunoterapia adoptiva
|
SG11201702895SA
(en)
|
2014-10-08 |
2017-05-30 |
Novartis Ag |
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
|
US20170239294A1
(en)
|
2014-10-15 |
2017-08-24 |
Novartis Ag |
Compositions and methods for treating b-lymphoid malignancies
|
CA3008162A1
(en)
|
2014-12-15 |
2016-06-23 |
The Regents Of The University Of California |
Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
|
WO2016102965A1
(en)
|
2014-12-24 |
2016-06-30 |
Ucl Business Plc |
Cell
|
JP2018500944A
(ja)
|
2014-12-29 |
2018-01-18 |
ノバルティス アーゲー |
キメラ抗原受容体発現細胞の製造法
|
WO2016115482A1
(en)
|
2015-01-16 |
2016-07-21 |
Novartis Pharma Ag |
Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
WO2016164580A1
(en)
|
2015-04-07 |
2016-10-13 |
Novartis Ag |
Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
|
DK3280729T3
(da)
|
2015-04-08 |
2022-07-25 |
Novartis Ag |
Cd20-behandlinger, cd22-behandlinger og kombinationsbehandlinger med en cd19-kimær antigenreceptor (car)-udtrykkende celle
|
ES2948133T3
(es)
|
2015-04-17 |
2023-08-31 |
Novartis Ag |
Métodos para mejorar la eficacia y expansión de células que expresan un receptor de antígeno quimérico
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
CA2992551A1
(en)
|
2015-07-21 |
2017-01-26 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
US11667691B2
(en)
|
2015-08-07 |
2023-06-06 |
Novartis Ag |
Treatment of cancer using chimeric CD3 receptor proteins
|
EP3344996A2
(de)
|
2015-09-03 |
2018-07-11 |
The Trustees Of The University Of Pennsylvania |
Biomarker zur vorhersage des zytokin-freisetzungssyndroms
|
CA2999070A1
(en)
|
2015-09-17 |
2017-03-23 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
CN105924530B
(zh)
*
|
2015-10-13 |
2019-08-06 |
中国人民解放军总医院 |
嵌合抗原受体及其基因和重组表达载体、car20-nkt细胞及其制备方法和应用
|
BR112018011089A2
(pt)
|
2015-12-04 |
2018-12-04 |
Intellia Therapeutics Inc |
composições e métodos para a imuno-oncologia
|
MA44140A
(fr)
|
2015-12-22 |
2021-05-19 |
Dana Farber Cancer Inst Inc |
Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse
|
SG11201805449PA
(en)
|
2015-12-28 |
2018-07-30 |
Novartis Ag |
Methods of making chimeric antigen receptor -expressing cells
|
CN109072195A
(zh)
|
2015-12-30 |
2018-12-21 |
诺华股份有限公司 |
具有增强功效的免疫效应细胞疗法
|
CN109153714A
(zh)
|
2016-03-04 |
2019-01-04 |
诺华股份有限公司 |
表达多重嵌合抗原受体(car)分子的细胞及其用途
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
CN105949317B
(zh)
*
|
2016-04-12 |
2019-07-02 |
上海优卡迪生物医药科技有限公司 |
抗cd20嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用
|
SG11201809041TA
(en)
|
2016-04-15 |
2018-11-29 |
Novartis Ag |
Compositions and methods for selective protein expression
|
CN105968210B
(zh)
*
|
2016-05-13 |
2019-05-31 |
深圳生创精准医疗科技有限公司 |
靶向cd22的强杀伤性嵌合抗原受体t细胞及其在制备治疗肿瘤的药物中的用途
|
US20210177896A1
(en)
|
2016-06-02 |
2021-06-17 |
Novartis Ag |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
CN110461315A
(zh)
|
2016-07-15 |
2019-11-15 |
诺华股份有限公司 |
使用与激酶抑制剂组合的嵌合抗原受体治疗和预防细胞因子释放综合征
|
BR112019001570A2
(pt)
|
2016-07-28 |
2019-07-09 |
Novartis Ag |
terapias de combinação de receptores de antígeno quiméricos e inibidores de pd-1
|
JP2019527696A
(ja)
|
2016-08-01 |
2019-10-03 |
ノバルティス アーゲー |
プロm2マクロファージ分子の阻害剤と組み合わせてキメラ抗原受容体を用いる癌の処置
|
EP3523290A4
(de)
|
2016-09-30 |
2020-07-29 |
Novartis AG |
Immuneffektorzelltherapien mit verbesserter wirksamkeit
|
EP3523331A1
(de)
|
2016-10-07 |
2019-08-14 |
Novartis AG |
Chimäre antigenrezeptoren zur behandlung von krebs
|
EP4043485A1
(de)
|
2017-01-26 |
2022-08-17 |
Novartis AG |
Cd28-zusammensetzungen und verfahren für chimäre antigenrezeptortherapie
|
JP2020506700A
(ja)
|
2017-01-31 |
2020-03-05 |
ノバルティス アーゲー |
多重特異性を有するキメラt細胞受容体タンパク質を用いた癌の治療
|
WO2018160731A1
(en)
|
2017-02-28 |
2018-09-07 |
Novartis Ag |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
JP2020513828A
(ja)
|
2017-03-22 |
2020-05-21 |
ノバルティス アーゲー |
増強された有効性を有するバイオマーカー及びcar t細胞療法
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
EP3615055A1
(de)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Zellen, die einen auf bcma abzielenden chimären antigenrezeptor exprimieren, und kombinationsbehandlung mit einem gamma-sekretase-inhibitor
|
BR112020007576A2
(pt)
|
2017-10-18 |
2020-09-24 |
Novartis Ag |
composições e métodos para degradação de proteína seletiva
|
BR112020007710A2
(pt)
|
2017-10-25 |
2020-10-20 |
Novartis Ag |
métodos para produzir células que expressam receptor de antígeno quimérico
|
AU2018369883A1
(en)
|
2017-11-15 |
2020-05-28 |
Novartis Ag |
BCMA-targeting chimeric antigen receptor, CD19-targeting chimeric antigen receptor, and combination therapies
|
AU2018375738A1
(en)
|
2017-11-30 |
2020-06-11 |
Novartis Ag |
BCMA-targeting chimeric antigen receptor, and uses thereof
|
CN112218651A
(zh)
|
2018-01-08 |
2021-01-12 |
诺华公司 |
用于与嵌合抗原受体疗法组合的免疫增强rna
|
EP3752203A1
(de)
|
2018-02-13 |
2020-12-23 |
Novartis AG |
Chimäre antigenrezeptortherapie in kombination mit il-15r und il15
|
US20200061113A1
(en)
|
2018-04-12 |
2020-02-27 |
Novartis Ag |
Chimeric antigen receptor therapy characterization assays and uses thereof
|
EP3784351A1
(de)
|
2018-04-27 |
2021-03-03 |
Novartis AG |
Car-t-zelltherapien mit erhöhter wirksamkeit
|
EP3788369A1
(de)
|
2018-05-01 |
2021-03-10 |
Novartis Ag |
Biomarker zur auswertung von car-t-zellen zur vorhersage des klinischen ergebnisses
|
US20200085869A1
(en)
|
2018-05-16 |
2020-03-19 |
Novartis Ag |
Therapeutic regimens for chimeric antigen receptor therapies
|
US20210213063A1
(en)
|
2018-05-25 |
2021-07-15 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
KR20210020932A
(ko)
|
2018-06-13 |
2021-02-24 |
노파르티스 아게 |
Bcma 키메라 항원 수용체 및 이의 용도
|
EP3844265A2
(de)
|
2018-08-31 |
2021-07-07 |
Novartis AG |
Verfahren zur herstellung von zellen zur expression des chimären antigenrezeptors
|
AU2019331496A1
(en)
|
2018-08-31 |
2021-03-18 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
US20220047633A1
(en)
|
2018-09-28 |
2022-02-17 |
Novartis Ag |
Cd22 chimeric antigen receptor (car) therapies
|
EP3856782A1
(de)
|
2018-09-28 |
2021-08-04 |
Novartis AG |
Chimärer cd19-antigen-rezeptor (car) und cd22-car-kombinationstherapien
|
WO2020176397A1
(en)
|
2019-02-25 |
2020-09-03 |
Novartis Ag |
Mesoporous silica particles compositions for viral delivery
|
US20230074800A1
(en)
|
2019-03-21 |
2023-03-09 |
Novartis Ag |
Car-t cell therapies with enhanced efficacy
|
US20220168389A1
(en)
|
2019-04-12 |
2022-06-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
WO2020219742A1
(en)
|
2019-04-24 |
2020-10-29 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
US11975026B2
(en)
|
2019-11-26 |
2024-05-07 |
Novartis Ag |
CD19 and CD22 chimeric antigen receptors and uses thereof
|
BR112022010206A2
(pt)
|
2019-11-26 |
2022-11-29 |
Novartis Ag |
Receptores de antígeno quiméricos e usos dos mesmos
|
US20230111593A1
(en)
|
2020-02-14 |
2023-04-13 |
Novartis Ag |
Method of predicting response to chimeric antigen receptor therapy
|
BR112022016633A2
(pt)
|
2020-02-27 |
2022-12-13 |
Novartis Ag |
Métodos para produzir células que expressam receptor de antígeno quimérico
|